Table 1. Characteristics of hyperuricemic patients stratified by baseline serum uric acid categories*.
| Serum uric acid level | <6 | 6–8 | 8–10 | >10 | p-trend |
|---|---|---|---|---|---|
| (mg/dL) | N = 153 | N = 228 | N = 212 | N = 146 | |
| Demographics | |||||
| Age (years) | 63.0 (1.2) | 63.6 (1.0) | 62.7 (1.0) | 62.8 (1.2) | 1.0 |
| Male (%) | 95(62.1%) | 132 (60.5%) | 122 (62.3%) | 97 (67.8%) | 0.5 |
| Smoking (%) | 59 (38.6%) | 80 (35.1%) | 79 (37.2%) | 64 (43.8%) | 0.4 |
| Comorbidity | |||||
| Hypertension (%) | 88 (57.5%) | 145 (65.6%) | 138 (69.8%) | 97 (67.8%) | 0.09 |
| Cardiovascular disease (%) | 26 (17.0%) | 53 (23.3%) | 48 (22.6%) | 34 (23.3%) | 0.5 |
| Diabetes (%) | 72 (47.1%) | 95 (41.7%) | 75 (35.6%) | 53 (36.3%) | 0.1 |
| Baseline clinical characteristics | |||||
| Systolic blood pressure (mmHg) | 136.3 (2.0) | 137.7 (1.6) | 138.4 (1.7) | 139.7(2.1) | 0.3 |
| Diastolic blood pressure (mmHg) | 75.4 (2.2) | 77.1 (1.8) | 81.7 (1.9) | 79.4(2.3) | 0.1 |
| Body mass index (kg/m2) | 24.0 (0.4) | 25.1 (0.3) | 25.1 (0.3) | 25.3 (0.4) | 0.03 |
| Serum total cholesterol (mg/dL) | 191.9(5.7) | 197.7 (4.7) | 197.2 (5.0) | 203.0 (6.0) | 0.2 |
| Serum triglyceride (mg/dL) | 221.8 (22.6) | 187.4 (18.8) | 183.9(19.9) | 176.2 (24.1) | 0.2 |
| Serum creatinine (mg/dL) | 1.58 (0.18) | 1.80 (0.15) | 2.13 (0.16) | 2.51 (0.19) | <0.001 |
| Proteinuria (Yes vs. No) (%) | 61 (43.3%) | 100 (47.6%) | 92 (45.5%) | 63 (49.2%) | 0.8 |
| eGFR (ml/min/1.73m2) | 74.7 (2.5) | 57.9 (2.1) | 52.6 (2.2) | 46.3 (2.7) | <0.001 |
| Baseline medication | |||||
| Allopurinol (%) | 32 (20.9%) | 66 (29.0%) | 87 (41.0%) | 79 (54.1%) | <0.001 |
| ACEI/ARB (%) | 70 (45.8%) | 123 (54.0%) | 127 (59.9%) | 84 (57.5%) | 0.05 |
* Characteristics of CKD patients are given as percentage for each categorical variable (e.g., hypertension) or arithmetic mean (standard error) (e.g., age) for each continuous variable.
Abbreviations: ACEI/ARB, angiotensin converting enzyme inhibitor/ AT1 receptor antagonist; eGFR, estimated glomerular filtration rate.